TY - JOUR
T1 - American Registry of Ambulatory or acutely decompensated heart failure (AMERICCAASS Registry)
T2 - First 1000 patients
AU - Gómez-Mesa, Juan Esteban
AU - Gutiérrez-Posso, Juliana María
AU - Escalante-Forero, Manuela
AU - Córdoba-Melo, Brayan Daniel
AU - Cárdenas-Marín, Paula Andrea
AU - Perna, Eduardo R.
AU - Valle-Ramos, Mádelyn Raquel
AU - Giraldo-González, Germán Camilo
AU - Flórez-Alarcón, Noel Alberto
AU - Rodríguez-Caballero, Ida Fabiola
AU - Núñez-Carrizo, Cristian
AU - Cabral-Gueyraud, Luz Teresa
AU - Marte-Arias, Sarah Raquel
AU - Hardin, Elizabeth Ashley
AU - Álvarez-Sangabriel, Amada
AU - Menjívar-De Ramos, María Eugenia
AU - van der Hilst, Kwame
AU - Cruz-Díaz, Licurgo Jacob
AU - Fausto Ovando, Sergio Roberto
AU - Rodríguez, Luis Arturo
AU - Escalante, Juan Pablo
AU - Ormaechea-Gorricho, Gabriela
AU - Bornancini, Norberto Raul
AU - Rodríguez-González, María Juliana
AU - Campbell-Quintero, Sebastián
AU - González-Hormostay, Raquel E.
AU - Oviedo-Pereira, Guillermo
AU - Trout-Guardiola, Guillermo
AU - Encina, Juan Justiniano
AU - Jerez-Castro, Ana Margarita
AU - Drazner, Mark
AU - Quesada-Chaves, Daniel
AU - Romero-Guerra, Alexander
AU - Rossel-Mariángel, Víctor Alejandro
AU - Speranza, Mario
N1 - Publisher Copyright:
© 2023 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
PY - 2024/2
Y1 - 2024/2
N2 - Background: About 80% of cardiovascular diseases (including heart failure [HF]) occur in low-income and developing countries. However, most clinical trials are conducted in developed countries. Hypothesis: The American Registry of Ambulatory or Acutely Decompensated Heart Failure (AMERICCAASS) aims to describe the sociodemographic characteristics of HF, comorbidities, clinical presentation, and pharmacological management of patients with ambulatory or acutely decompensated HF in America. Methodology: Descriptive, observational, prospective, and multicenter registry, which includes patients >18 years with HF in an outpatient or hospital setting. Collected information is stored in the REDCap electronic platform. Quantitative variables are defined according to the normality of the variable using the Shapiro–Wilk test. Results: This analysis includes data from the first 1000 patients recruited. 63.5% were men, the median age of 66 years (interquartile range 56.7–75.4), and 77.6% of the patients were older than 55 years old. The percentage of use of the four pharmacological pillars at the time of recruitment was 70.7% for beta-blockers (BB), 77.4% for angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB II)/angiotensin receptor-neprilysin inhibitor (ARNI), 56.8% for mineralocorticoid receptor antagonists (MRA), and 30.7% for sodium–glucose cotransporter type-2 inhibitors (SGLT2i). The main cause of decompensation in hospitalized patients was HF progression (64.4%), and the predominant hemodynamic profile was wet-warm (68.3%). Conclusions: AMERICCAASS is the first continental registry to include hospitalized or outpatient patients with HF. Regarding optimal medical therapy, approximately a quarter of the patients still need to receive BB and ACEI/ARB/ARNI, less than half do not receive MRA, and more than two-thirds do not receive SGLT2i.
AB - Background: About 80% of cardiovascular diseases (including heart failure [HF]) occur in low-income and developing countries. However, most clinical trials are conducted in developed countries. Hypothesis: The American Registry of Ambulatory or Acutely Decompensated Heart Failure (AMERICCAASS) aims to describe the sociodemographic characteristics of HF, comorbidities, clinical presentation, and pharmacological management of patients with ambulatory or acutely decompensated HF in America. Methodology: Descriptive, observational, prospective, and multicenter registry, which includes patients >18 years with HF in an outpatient or hospital setting. Collected information is stored in the REDCap electronic platform. Quantitative variables are defined according to the normality of the variable using the Shapiro–Wilk test. Results: This analysis includes data from the first 1000 patients recruited. 63.5% were men, the median age of 66 years (interquartile range 56.7–75.4), and 77.6% of the patients were older than 55 years old. The percentage of use of the four pharmacological pillars at the time of recruitment was 70.7% for beta-blockers (BB), 77.4% for angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB II)/angiotensin receptor-neprilysin inhibitor (ARNI), 56.8% for mineralocorticoid receptor antagonists (MRA), and 30.7% for sodium–glucose cotransporter type-2 inhibitors (SGLT2i). The main cause of decompensation in hospitalized patients was HF progression (64.4%), and the predominant hemodynamic profile was wet-warm (68.3%). Conclusions: AMERICCAASS is the first continental registry to include hospitalized or outpatient patients with HF. Regarding optimal medical therapy, approximately a quarter of the patients still need to receive BB and ACEI/ARB/ARNI, less than half do not receive MRA, and more than two-thirds do not receive SGLT2i.
KW - America
KW - ambulatory
KW - heart failure
KW - hospitable
UR - http://www.scopus.com/inward/record.url?scp=85178247056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178247056&partnerID=8YFLogxK
U2 - 10.1002/clc.24182
DO - 10.1002/clc.24182
M3 - Article
C2 - 38032698
AN - SCOPUS:85178247056
SN - 0160-9289
VL - 47
JO - Clinical Cardiology
JF - Clinical Cardiology
IS - 2
M1 - e24182
ER -